liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction
Sahlgrenska University Hospital/Östra, Göteborg, Sweden, Clinical Experimental Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/Östra, 416 85 Göteborg, Sweden.
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Health Sciences, Cardiology . Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.ORCID iD: 0000-0002-2608-2062
Akademiska Hospital, Uppsala, Sweden.
Sahlgrenska University Hospital/Östra, Göteborg, Sweden.
2002 (English)In: Clinical Therapeutics, ISSN 0149-2918, Vol. 24, no 5, 752-765 p.Article in journal (Refereed) Published
Abstract [en]

Background: Thrombin generation and platelet aggregation in the disrupted atherosclerotic plaque are the major reasons for thrombus formation associated with acute coronary events. AR-C69931MX is a new agent that inhibits adenosine diphosphate-induced platelet aggregation by antagonism of the P2T purinoceptor. Objective: This study assessed the safety profile, tolerability, and plasma concentrations at steady state of intravenous AR-C69931MX in patients with unstable angina pectoris or non-Q-wave myocardial infarction (MI). Methods: This was a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Patients with unstable angina or non-Q-wave MI were randomized to a 72-hour infusion of AR-C69931MX or placebo as adjunctive therapy to aspirin and low-molecular-weight heparin. Other treatment was at the discretion of the local investigator. Outcomes were assessed at 30 days. Results: Ninety-four patients were randomized and 91 received treatment (45 AR-C69931MX, 46 placebo). Plasma concentrations of AR-C69931MX were within the expected range, there were no signs of accumulation, and interindividual variability in clearance was low. Four patients receiving AR-C69931MX discontinued treatment due to minor bleeding events, and 5 patients receiving placebo discontinued treatment due to other adverse events or deterioration in their condition. No serious bleeding events were seen during treatment. The incidence of =1 episode of minor bleeding was slightly higher in patients receiving AR-C69931MX compared with those receiving placebo (38% vs 26%, respectively). The drug was well tolerated hemodynamically, and there were no significant changes in other laboratory values between groups. Conclusions: As adjunctive therapy to aspirin and low-molecular-weight heparin in patients with unstable angina or non-Q-wave MI, intravenous AR-C69931MX was well tolerated, with no difference in the incidence of serious adverse events compared with placebo.

Place, publisher, year, edition, pages
2002. Vol. 24, no 5, 752-765 p.
Keyword [en]
Adjunctive therapy, Atherosclerotic plaque, Hemodynamic tolerance, Ischemic heart disease, Platelet aggregation, Unstable coronary artery disease
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-46980DOI: 10.1016/S0149-2918(02)85149-9OAI: diva2:267876
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2013-09-11

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Swahn, Eva
By organisation
Faculty of Health SciencesCardiology Department of Cardiology
In the same journal
Clinical Therapeutics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 6 hits
ReferencesLink to record
Permanent link

Direct link